Article 23 Dec 2024 Novel Biosimilar Anti-Trust Complaint Involving Janssen's STELARA (Ustekinumab) Dismissed By The Canadian Competition Tribunal Canada Anti-trust
Article 23 Dec 2024 Federal Court Of Appeal: No Single Or Mandatory Approach To Obviousness; Prior Art Disclosing Multiple Options Can Anticipate Canada IP
Article 19 Dec 2024 Federal Court Of Appeal: Patented Medicine Prices Review Board "Crashed" Through "Guardrails" In Attempt To Regulate Unpatented Medicine Canada IP
Article 29 Aug 2024 JAMP Launches Novel Competition Complaint Alleging Janssen Abused Its Dominance Over Stelara (Ustekinumab) Canada IP
Article 25 Jun 2021 Federal Court Of Appeal Affirms: Summary Adjudication Of Patent Disputes Is Viable In Canada Canada IP